university of south florida
Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinson’s disease
Tampa, FL (Feb. 10, 2011) — Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson’s disease receiving standard dopamine therapy, an international study led by the University of South Florida found.
Results of th…
Stimulating the brain’s immune response may provide treatment for Alzheimer’s disease
A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer’s disease (AD) has been discovered by researchers at the University of South Florida’s Department of Psychiatry and the Center of Exce…
Blue-green algae tested for treating ALS
Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, Universit…
Environmental pharmaceutical contamination removed by Octolig
An article in the current issue of TECHNOLOGY & INNOVATION, Proceedings of the National Academy of Inventors http://www.cognizantcommunication.com/filecabinet/Technology/techinnovation.html reports on the removal of certain dyes and the antibio…
UT professors find mixing business with politics pays off
Now that the 2010 election is over, here is something to consider for the 2012 race: If you want to fatten your company’s profits, contribute to a political campaign.
A study by two College of Business Administration professors at the University o…
Nicotine antagonist relieves depression in children with Tourette’s
A well-tolerated drug that blocks nicotine receptors in the brain appears to relieve depression and mood instability in children and adolescents with Tourette’s syndrome, a preliminary study has found. The multicenter, placebo-controlled study of the drug mecamylamine is published in the latest issue of the journal Depression and Anxiety. “These preliminary findings are consistent with anecdotal observations that mecamylamine stabilizes mood,” said lead author Douglas Shytle. “In addition, this is the first clinical evidence supporting the hypothesis that many antidepressants function, in part, by inhibiting nicotinic receptors.”